Business Context and Reporting Period
This Form 8-K is a current report filed by Ocuphire Pharma, Inc. (trading symbol: OCUP) on October 14, 2022. The filing serves as a Regulation FD disclosure regarding the presentation of new data and updates on the Company's APX3330 clinical program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on clinical program updates rather than financial performance metrics.
Material Changes
The material event disclosed is the presentation of new clinical data for the APX3330 program. No financial material changes or comparative period data are included in this document.
Guidance, Outlook, and Risks
- Outlook: The Company presented updates on its APX3330 clinical program, with the full presentation included as Exhibit 99.1.
- Risks and Forward-Looking Statements: The filing contains forward-looking statements based on current expectations. These are not guarantees of future performance and are subject to risks that may cause actual results to differ materially.
- Legal Status: Information in this report is furnished pursuant to Item 7.01 and is not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation) for specific details on the APX3330 clinical data.
- Verify the Company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K does not contain financial statements.
- Assess the timeline for future clinical milestones based on the presentation data.
- Confirm the trading status of OCUP on the Nasdaq Stock Market LLC.